217 related articles for article (PubMed ID: 9315632)
1. Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain.
Webster MK; Donoghue DJ
Mol Cell Biol; 1997 Oct; 17(10):5739-47. PubMed ID: 9315632
[TBL] [Abstract][Full Text] [Related]
2. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4.
Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ
Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587
[TBL] [Abstract][Full Text] [Related]
3. The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum.
Lievens PM; Liboi E
J Biol Chem; 2003 May; 278(19):17344-9. PubMed ID: 12624096
[TBL] [Abstract][Full Text] [Related]
4. Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II.
Webster MK; D'Avis PY; Robertson SC; Donoghue DJ
Mol Cell Biol; 1996 Aug; 16(8):4081-7. PubMed ID: 8754806
[TBL] [Abstract][Full Text] [Related]
5. Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation.
Hart KC; Robertson SC; Donoghue DJ
Mol Biol Cell; 2001 Apr; 12(4):931-42. PubMed ID: 11294897
[TBL] [Abstract][Full Text] [Related]
6. Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformation.
Chen J; Williams IR; Lee BH; Duclos N; Huntly BJ; Donoghue DJ; Gilliland DG
Blood; 2005 Jul; 106(1):328-37. PubMed ID: 15784730
[TBL] [Abstract][Full Text] [Related]
7. Effect of transmembrane and kinase domain mutations on fibroblast growth factor receptor 3 chimera signaling in PC12 cells. A model for the control of receptor tyrosine kinase activation.
Raffioni S; Zhu YZ; Bradshaw RA; Thompson LM
J Biol Chem; 1998 Dec; 273(52):35250-9. PubMed ID: 9857065
[TBL] [Abstract][Full Text] [Related]
8. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
Naski MC; Wang Q; Xu J; Ornitz DM
Nat Genet; 1996 Jun; 13(2):233-7. PubMed ID: 8640234
[TBL] [Abstract][Full Text] [Related]
9. Integrative nuclear FGFR1 signaling (INFS) pathway mediates activation of the tyrosine hydroxylase gene by angiotensin II, depolarization and protein kinase C.
Peng H; Myers J; Fang X; Stachowiak EK; Maher PA; Martins GG; Popescu G; Berezney R; Stachowiak MK
J Neurochem; 2002 May; 81(3):506-24. PubMed ID: 12065659
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of endochondral bone growth and joint development by FGFR1 and FGFR3 tyrosine kinase domains.
Wang Q; Green RP; Zhao G; Ornitz DM
Development; 2001 Oct; 128(19):3867-76. PubMed ID: 11585811
[TBL] [Abstract][Full Text] [Related]
11. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.
Chesi M; Brents LA; Ely SA; Bais C; Robbiani DF; Mesri EA; Kuehl WM; Bergsagel PL
Blood; 2001 Feb; 97(3):729-36. PubMed ID: 11157491
[TBL] [Abstract][Full Text] [Related]
12. The cytoplasmic tyrosine kinase Pyk2 as a novel effector of fibroblast growth factor receptor 3 activation.
Meyer AN; Gastwirt RF; Schlaepfer DD; Donoghue DJ
J Biol Chem; 2004 Jul; 279(27):28450-7. PubMed ID: 15105428
[TBL] [Abstract][Full Text] [Related]
13. Mapping ligand binding domains in chimeric fibroblast growth factor receptor molecules. Multiple regions determine ligand binding specificity.
Chellaiah A; Yuan W; Chellaiah M; Ornitz DM
J Biol Chem; 1999 Dec; 274(49):34785-94. PubMed ID: 10574949
[TBL] [Abstract][Full Text] [Related]
14. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism.
Su WC; Kitagawa M; Xue N; Xie B; Garofalo S; Cho J; Deng C; Horton WA; Fu XY
Nature; 1997 Mar; 386(6622):288-92. PubMed ID: 9069288
[TBL] [Abstract][Full Text] [Related]
15. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.
Webster MK; Donoghue DJ
EMBO J; 1996 Feb; 15(3):520-7. PubMed ID: 8599935
[TBL] [Abstract][Full Text] [Related]
16. Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype.
Bellus GA; Spector EB; Speiser PW; Weaver CA; Garber AT; Bryke CR; Israel J; Rosengren SS; Webster MK; Donoghue DJ; Francomano CA
Am J Hum Genet; 2000 Dec; 67(6):1411-21. PubMed ID: 11055896
[TBL] [Abstract][Full Text] [Related]
17. Ligand-independent activation of fibroblast growth factor receptors by point mutations in the extracellular, transmembrane, and kinase domains.
Neilson KM; Friesel R
J Biol Chem; 1996 Oct; 271(40):25049-57. PubMed ID: 8798788
[TBL] [Abstract][Full Text] [Related]
18. FRS2 proteins recruit intracellular signaling pathways by binding to diverse targets on fibroblast growth factor and nerve growth factor receptors.
Ong SH; Guy GR; Hadari YR; Laks S; Gotoh N; Schlessinger J; Lax I
Mol Cell Biol; 2000 Feb; 20(3):979-89. PubMed ID: 10629055
[TBL] [Abstract][Full Text] [Related]
19. The FGF receptor-1 tyrosine kinase domain regulates myogenesis but is not sufficient to stimulate proliferation.
Kudla AJ; Jones NC; Rosenthal RS; Arthur K; Clase KL; Olwin BB
J Cell Biol; 1998 Jul; 142(1):241-50. PubMed ID: 9660877
[TBL] [Abstract][Full Text] [Related]
20. Sef inhibits fibroblast growth factor signaling by inhibiting FGFR1 tyrosine phosphorylation and subsequent ERK activation.
Kovalenko D; Yang X; Nadeau RJ; Harkins LK; Friesel R
J Biol Chem; 2003 Apr; 278(16):14087-91. PubMed ID: 12604616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
